Jhl Capital Group buys $95,850,000 stake in Relypsa Inc (RLYP)

Relypsa Inc (RLYP) : Jhl Capital Group scooped up 750,000 additional shares in Relypsa Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 3,000,000 shares of Relypsa Inc which is valued at $95,850,000.Relypsa Inc makes up approximately 12.72% of Jhl Capital Group’s portfolio.

Other Hedge Funds, Including , Cubist Systematic Strategies sold out all of its stake in RLYP during the most recent quarter. The investment firm sold 11,032 shares of RLYP which is valued $352,472.Janus Capital Management boosted its stake in RLYP in the latest quarter, The investment management firm added 130,742 additional shares and now holds a total of 4,513,955 shares of Relypsa Inc which is valued at $144,220,862. Relypsa Inc makes up approx 0.12% of Janus Capital Management’s portfolio.Blackrock Institutional Trust Company N.a. boosted its stake in RLYP in the latest quarter, The investment management firm added 40,405 additional shares and now holds a total of 769,843 shares of Relypsa Inc which is valued at $24,596,484. Cornerstone Financial Partners sold out all of its stake in RLYP during the most recent quarter. The investment firm sold 17,574 shares of RLYP which is valued $560,786.Emerald Mutual Fund Advisers Trust reduced its stake in RLYP by selling 71,760 shares or 13.83% in the most recent quarter. The Hedge Fund company now holds 447,099 shares of RLYP which is valued at $14,280,342. Relypsa Inc makes up approx 0.76% of Emerald Mutual Fund Advisers Trust’s portfolio.

On the company’s financial health, Relypsa Inc reported $-1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.18 according to the earnings call on May 4, 2016. Analyst had a consensus of $-1.44. The company had revenue of $12.40 million for the quarter, compared to analysts expectations of $7.10 million. During the same quarter in the previous year, the company posted $-0.78 EPS.

Many Wall Street Analysts have commented on Relypsa Inc. Relypsa Inc was Downgraded by Stifel to ” Hold” on Aug 22, 2016. Relypsa Inc was Downgraded by Cantor Fitzgerald to ” Hold” on Jul 26, 2016. Relypsa Inc was Downgraded by Guggenheim to ” Neutral” on Jul 26, 2016.

Relypsa Inc. is a biopharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal cardiovascular and metabolic diseases. The Company’s lead product candidate Patiromer for Oral Suspension (Patiromer FOS) is for the treatment of hyperkalemia a life-threatening condition defined as abnormally elevated levels of potassium in the blood. Its New Drug Application (NDA) for Patiromer FOS was accepted for filing by the United States Food and Drug Administration or FDA. The Company’s NDA is supported by a clinical development program consisting of eight clinical trials: three Phase I trials four Phase II trials and one two-part Phase III trial conducted under a Special Protocol Assessment or SPA. The active ingredient is a cross-linked polymeric bead with a calcium containing counterion. The Company has the global royalty-free commercialization rights to Patiromer FOS.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *